Caris Life Sciences

Forecast & Rating14 analysts currently cover Caris Life Sciences, with about 71.4% giving a positive rating — meaning they expect the stock to rise. The average price target is $32.08, about 1.2% upside from the current price of $31.71. Price targets span a fair range, indicating some disagreement among institutions. For you, this means most professionals who study Caris Life Sciences closely still see room for the stock to rise. Data as of Oct 22, 2026; for reference only and not investment advice.